Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis.

Abstract:

BACKGROUND:Recent studies suggest a relatively high prevalence of autoimmune disorders (AD) among primary CNS lymphoma (PCNSL) patients, however, the literature is limited to case reports. To gain a better understanding of AD-PCNSL we reviewed and analyzed all cases described in the literature. METHODS:We searched the MEDLINE database using the search terms 'central nervous system lymphoma' or 'CNS lymphoma' along with AD-related terms. We selected 39 records for qualitative synthesis of data and identified 50 AD-PCNSL. Clinical, imaging and outcome data were collected. Overall survival (OS) was analyzed with the Kaplan-Meier method. Univariate and multivariate analyses were performed using log rank test and Cox proportional hazard model. RESULTS:Most common AD were systemic lupus erythematosus (24%), multiple sclerosis (16%), and myasthenia gravis (14%). All patients had received immunosuppressants for their AD. Median interval from AD until PCNSL diagnosis was 108 months (range: 11-420). Male-to-female ratio was 0.42 and AD-PCNSL was diagnosed at a median age of 57 years (range: 2-88). On imaging lesions typically localized to the hemispheres (65%) and displayed peripheral enhancement (74%). Pathological evaluation revealed diffuse large-B-cell lymphoma (DLBCL) subtype (80%) and Epstein-Barr virus positivity (75%) in most AD-PCNSL. Median OS was 31 months. Age > 60 years (p = 0.014) was identified as a significant prognostic factor. CONCLUSIONS:AD requiring immunosuppression appear over-represented in the population of PCNSL patients. Aggressive polychemotherapy can accomplish long term OS in AD-PCNSL comparable to immunocompetent patients. Age > 60 may serve as a prognostic factor.

journal_name

J Neurooncol

authors

Kaulen LD,Karschnia P,Dietrich J,Baehring JM

doi

10.1007/s11060-020-03583-9

subject

Has Abstract

pub_date

2020-08-01 00:00:00

pages

153-159

issue

1

eissn

0167-594X

issn

1573-7373

pii

10.1007/s11060-020-03583-9

journal_volume

149

pub_type

杂志文章
  • Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system.

    abstract:BACKGROUND:Prior studies have highlighted infratentorial tumor location as a prognostic factor for solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) of the central nervous system (CNS), and spinal location is considered a positive prognostic factor for other tumors of the CNS. While SFT/HPC of the CNS is known ...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-019-03177-0

    authors: Boyett D,Kinslow CJ,Bruce SS,Sonabend AM,Rae AI,McKhann GM,Sisti MB,Bruce JN,Cheng SK,Wang TJC

    更新日期:2019-07-01 00:00:00

  • Radio-induced gliomas: 20-year experience and critical review of the pathology.

    abstract::The authors report their personal experience with a surgical series of 16 cases of cerebral radiation-induced gliomas, defining diagnostic criteria and surgical and clinical characteristics. There were ten males and six females, with a median age of 45.9 years. Irradiation had initially been given for acute lymphoblas...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-008-9565-x

    authors: Salvati M,D'Elia A,Melone GA,Brogna C,Frati A,Raco A,Delfini R

    更新日期:2008-09-01 00:00:00

  • Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

    abstract::Radiation (RT) is critical to the treatment of high-grade gliomas (HGGs) but cures remain elusive. The BRAF mutation V600E is critical to the pathogenesis of 10-20% of pediatric gliomas, and a small proportion of adult HGGs. Here we aim to determine whether PLX4720, a specific BRAF V600E inhibitor, enhances the activi...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-015-1939-2

    authors: Dasgupta T,Olow AK,Yang X,Hashizume R,Nicolaides TP,Tom M,Aoki Y,Berger MS,Weiss WA,Stalpers LJ,Prados M,James CD,Mueller S,Haas-Kogan DA

    更新日期:2016-02-01 00:00:00

  • Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

    abstract::Brain tumor patients undergo various combinations therapies, leading to very complex and confusing imaging appearances on follow up MR imaging and hence, differentiating recurrent or progressing tumors from treatment induced necrosis or effects has always been a challenge in neuro-oncologic imaging. This particular to...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s11060-010-0139-3

    authors: Jain R,Narang J,Sundgren PM,Hearshen D,Saksena S,Rock JP,Gutierrez J,Mikkelsen T

    更新日期:2010-10-01 00:00:00

  • Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.

    abstract::The members of the PERNO Study Group were not individually captured in the metadata of the original publication. They are included in the metadata of this publication. ...

    journal_title:Journal of neuro-oncology

    pub_type: 已发布勘误

    doi:10.1007/s11060-017-2638-y

    authors: Franceschi E,Depenni R,Paccapelo A,Ermani M,Faedi M,Sturiale C,Michiara M,Servadei F,Pavesi G,Urbini B,Pisanello A,Crisi G,Cavallo MA,Dazzi C,Biasini C,Bertolini F,Mucciarini C,Pasini G,Baruzzi A,Brandes AA,PERNO

    更新日期:2018-01-01 00:00:00

  • Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.

    abstract::Patients with brain metastasis (BM) from renal cell carcinoma (RCC) are associated with poor prognosis. Between 1990 and 2015, data of consecutive RCC patients with BM were retrospectively analyzed from a urologic oncologic database. The treatment outcome was evaluated by overall survival (OS), which was defined as in...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-016-2238-2

    authors: Du Y,Pahernik S,Hadaschik B,Teber D,Duensing S,Jäger D,Hohenfellner M,Grüllich C

    更新日期:2016-10-01 00:00:00

  • Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature.

    abstract::This review identifies the current literature on the use of bevacizumab for cerebral radiation necrosis in patients with high-grade gliomas, summarizes the clinical course and complications following bevacizumab, and discusses the relative costs and benefits of this therapeutic option. A Medline search was conducted o...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s11060-013-1233-0

    authors: Lubelski D,Abdullah KG,Weil RJ,Marko NF

    更新日期:2013-12-01 00:00:00

  • Inhibition of glioma cell proliferation by neural stem cell factor.

    abstract::Neural stem cells (NSC) have unique differentiation-, proliferation-, and motility properties. To investigate whether they secrete factors that interfere with the proliferation of glioma cells, we grew glioma cells in conditioned medium (CM) obtained from cultures of neurospheres including neural stem / progenitor cel...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-004-7118-5

    authors: Suzuki T,Izumoto S,Wada K,Fujimoto Y,Maruno M,Yamasaki M,Kanemura Y,Shimazaki T,Okano H,Yoshimine T

    更新日期:2005-09-01 00:00:00

  • Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.

    abstract::Leptomeningeal dissemination of low-grade gliomas is an uncommon event. A 43-year old male presented with dizziness, gait ataxia, and diplopia. A nonenhancing lesion in the right cerebellar peduncle was identified, subtotally resected, and diagnosed as a grade II astrocytoma. After one year a nodular spread in the bra...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-009-0040-0

    authors: Passarin MG,Moretto G,Musso AM,Ottaviani S,Masotto B,Ghimenton C,Iuzzolino P,Buffone E,Rudà R,Soffietti R,Vattemi E,Pedersini R

    更新日期:2010-05-01 00:00:00

  • Human astrocytomas co-expressing Fas and Fas ligand also produce TGFbeta2 and Bcl-2.

    abstract::Human astrocytomas frequently co-express Fas (APO-1/CD95) and Fas ligand (FasL), yet do not appear to be overly susceptible to suicidal, fratricidal and immune-mediated elimination. This suggests that these gliomas have acquired mechanisms to prevent Fas-mediated apoptosis from occurring. Candidates for such a role in...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1023/a:1006311231189

    authors: Frankel B,Longo SL,Ryken TC

    更新日期:1999-01-01 00:00:00

  • Effect of calcium antagonists on regional cerebral blood flow in transplanted rat brain tumors.

    abstract::We studied the effect of intracarotid infusion of various calcium antagonists on regional CBF (rCBF) in the C6 rat glioma by a hydrogen clearance method. Nimodipine at doses of 0.1, 0.5 and 1 microgram/kg/min was found to produce tumor-specific increases in the rCBF (40.2 +/- 18.4%, p < 0.01, 67.8 +/- 32.6%, p < 0.001...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/BF00146078

    authors: Matsukado K,Ikezaki K,Nomura T,Fukui M

    更新日期:1996-01-01 00:00:00

  • Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK).

    abstract::Degradation and remodelling of the extracellular matrix has been investigated, with the main focus on the balance between matrix metalloproteinases (MMP) and tissue inhibitor of metalloproteinases (TIMP). Recent reports disclose the presence of a novel MMP-inhibiting cell membrane-anchored glycoprotein designated 'rev...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-008-9606-5

    authors: Yoshida D,Nomura R,Teramoto A

    更新日期:2008-09-01 00:00:00

  • Medulloblastoma with melanotic differentiation: case report and review of the literature.

    abstract::Medulloblastoma with melanotic differentiation, a rare variant of medulloblastoma, often carries a poor prognosis. We present such a case of a 4 year male with this rare, aggressive tumor. Additionally, we have reviewed the literature and report on the features important in the pathologic and radiologic diagnosis in t...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1007/s11060-010-0436-x

    authors: Phillips CL,Miles L,Jones BV,Sutton M,Crone K,Fouladi M

    更新日期:2011-07-01 00:00:00

  • Descriptive epidemiology of primary spinal cord tumors.

    abstract:OBJECT:There is little population-based data available on primary spinal cord tumors. Many of the existing statistics are not current or were obtained from surgical series. Historically, population-based data were collected only for malignant tumors, and only recently have data begun to be collected on non-malignant tu...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-007-9507-z

    authors: Schellinger KA,Propp JM,Villano JL,McCarthy BJ

    更新日期:2008-04-01 00:00:00

  • Neural cell adhesion molecule expression in human pituitary adenomas.

    abstract::Neural cell adhesion molecule (NCAM) is a cell surface glycoprotein whose expression may be important in metastatic or local growth of neoplasms. Expression of NCAM in human pituitary adenomas was assessed on snap-frozen and Bouin's and/or formalin-fixed, paraffin-embedded archival tissue using a sensitive alkaline ph...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/BF01053153

    authors: Kleinschmidt-DeMasters BK,Conway DR,Franklin WA,Lillehei KO,Kruse CA

    更新日期:1995-01-01 00:00:00

  • Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?

    abstract:UNLABELLED:Cranio-spinal irradiation is the gold standard treatment used in non metastatic medulloblastoma as prophylaxis against central nervous system (CNS) metastases. However, given the severe late effects caused by this procedure in children under 3 years of age, most pediatric oncologists are currently treating t...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/BF00146088

    authors: Dupuis-Girod S,Hartmann O,Benhamou E,Doz F,Mechinaud F,Bouffet E,Coze C,Kalifa C

    更新日期:1996-01-01 00:00:00

  • CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma.

    abstract::Cell differentiation agent-2 (CDA-2) is an extraction from healthy human urine consisting of primary organic acids and peptides, and it has been demonstrated to inhibit growth and induce differentiation in glioma and other cell lines. But the mechanism of CDA-2 remains unclear. In this study, we demonstrated that CDA-...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-012-0961-x

    authors: Xie YK,Huo SF,Zhang G,Zhang F,Lian ZP,Tang XL,Jin C

    更新日期:2012-11-01 00:00:00

  • Serum alkaline phosphatase and 30-day mortality after surgery for spinal metastatic disease.

    abstract:BACKGROUND:Elevated serum alkaline phosphatase has been previously studied as a biomarker for progression of metastatic disease and implicated in adverse skeletal events and worsened survival. The purpose of this study was to determine if serum alkaline phosphatase was a predictor of short-term mortality of patients un...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-018-2947-9

    authors: Karhade AV,Thio QCBS,Ogink PT,Schwab JH

    更新日期:2018-10-01 00:00:00

  • Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.

    abstract::Anti-PD-1/PD-L1 therapies have demonstrated activity in patients with advanced stage non-small cell lung cancer (NSCLC). However, little is known about the safety and feasibility of patients receiving anti-PD-1/PD-L1 therapy and stereotactic radiation for the treatment of brain metastases. Data were analyzed retrospec...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-017-2437-5

    authors: Ahmed KA,Kim S,Arrington J,Naghavi AO,Dilling TJ,Creelan BC,Antonia SJ,Caudell JJ,Harrison LB,Sahebjam S,Gray JE,Etame AB,Johnstone PA,Yu M,Perez BA

    更新日期:2017-06-01 00:00:00

  • Genetic variations in VEGF and VEGFR2 and glioblastoma outcome.

    abstract::Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) are central components in the development and progression of glioblastoma. To investigate if genetic variation in VEGF and VEGFR2 is associated with glioblastoma prognosis, we examined blood samples from 154 glioblastoma cases collected in Sweden and ...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-010-0504-2

    authors: Sjöström S,Wibom C,Andersson U,Brännström T,Broholm H,Johansen C,Collatz-Laier H,Liu Y,Bondy M,Henriksson R,Melin B

    更新日期:2011-09-01 00:00:00

  • EMPACT syndrome: limited evidence despite a high-risk cohort.

    abstract::Serious dermatologic adverse events such as erythema multiforme (EM) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) have been reported in patients receiving antiepileptic drugs (AEDs) and cranial radiotherapy (RT). Given the frequency of AED-associated rashes and the infrequency of serious dermatolo...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-014-1457-7

    authors: Bishop AJ,Chang M,Lacouture ME,Barker CA

    更新日期:2014-08-01 00:00:00

  • Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.

    abstract:BACKGROUND:Tumor treating fields (TTFields) are anti-mitotic, non-invasive loco-regional cancer therapy comprising low intensity, intermediate frequency alternating electric fields. TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 t...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11060-019-03361-2

    authors: Kim CY,Paek SH,Nam DH,Chang JH,Hong YK,Kim JH,Kim OL,Kim SH

    更新日期:2020-02-01 00:00:00

  • Extraneural metastatic medulloblastoma in an adult.

    abstract::Medulloblastoma is a rare malignancy in adults, accounting for approximately 1% of all primary brain tumors. Extraneural metastases have been reported in 10-30% of cases and most commonly involve bone; rarely lymph nodes, visceral organs and bone marrow may be involved with disease. We report here our experience with ...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-005-9087-8

    authors: Wendland MM,Shrieve DC,Watson GA,Chin SS,Blumenthal DT

    更新日期:2006-06-01 00:00:00

  • Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: case report.

    abstract:OBJECT:Prophylactic cranial irradiation (PCI) is commonly offered to patients with limited stage primary small cell lung cancer following a complete response. METHODS:We present the unique case of a 76-year-old woman treated with PCI with a dose of 30 Gy in 15 fractions, at 200 cGy per fraction who developed progressi...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-007-9384-5

    authors: D'Ambrosio DJ,Cohen RB,Glass J,Konski A,Buyyounouski MK,Feigenberg SJ

    更新日期:2007-10-01 00:00:00

  • Growth factors, glia and gliomas.

    abstract::The abilities of growth factors to cause normal cells to express the properties associated with transformed cells is discussed in specific reference to the oligodendrocyte-type-2 astrocyte (O-2A) progenitor cell. In the O-2A lineage, it has been possible to use growth factors and other defined molecules to induce or p...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1023/a:1005898228116

    authors: Noble M,Mayer-Pröschel M

    更新日期:1997-12-01 00:00:00

  • Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.

    abstract::Combination of procarbazine, lomustine and vincristine (PCV) with radiation therapy (RT) has been associated with longer survival in patients with anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA), especially in those with chromosome 1p/19q codeletion. We report a multicenter retrospective study ...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s11060-013-1288-y

    authors: Minniti G,Arcella A,Scaringi C,Lanzetta G,Di Stefano D,Scarpino S,Pace A,Giangaspero F,Osti MF,Enrici RM

    更新日期:2014-01-01 00:00:00

  • Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients.

    abstract::A historically controlled phase II study was undertaken to investigate the efficacy and toxicity of a postoperative treatment consisting of high-dose continuous tamoxifen, carboplatin and radiotherapy in patients with newly diagnosed glioblastoma. Between 1995 and 1998, 50 patients with newly diagnosed glioblastomas u...

    journal_title:Journal of neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1026533016912

    authors: Puchner MJ,Herrmann HD,Berger J,Cristante L

    更新日期:2000-09-01 00:00:00

  • Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.

    abstract:INTRODUCTION:Erlotinib and Gefitinib (EGFRi) are small molecules specifically inhibiting epidermal growth factor receptor (EGFR). We present here data of an exploratory study evaluating EGFRi monotherapy in patients with recurrent or progressive malignant glioma. PATIENTS:21 patients with recurrent or progressive mali...

    journal_title:Journal of neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11060-008-9608-3

    authors: Preusser M,Gelpi E,Rottenfusser A,Dieckmann K,Widhalm G,Dietrich W,Bertalanffy A,Prayer D,Hainfellner JA,Marosi C

    更新日期:2008-09-01 00:00:00

  • Phase II study of lonidamine plus radiotherapy in the treatment of brain metastases.

    abstract::Twenty-nine patients received the cytotoxic radiosensitizing agent lonidamine before, during, and after cranial irradiation for brain metastases. One patient was ineligible (meningioma). In 28 eligible patients, median survival was 29 weeks (range, 2 to > 220 weeks). Nine patients (32%) survived > 1 year and 3 (11%) s...

    journal_title:Journal of neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF01050258

    authors: Stewart DJ,Eapen L,Girard A,Verma S,Genest P,Evans WK

    更新日期:1993-01-01 00:00:00

  • Mitigation of radiation-induced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time.

    abstract:PURPOSE:Radiation-induced optic nerve damage was reduced by ramipril, a prodrug angiotensin-converting enzyme inhibitor (ACEI). This study was to determine the optimum dose and administration time of ramipril for mitigating radiation-induced optic neuropathy. MATERIALS AND METHOD:Adult Fischer 344 male rats were treat...

    journal_title:Journal of neuro-oncology

    pub_type: 杂志文章

    doi:10.1007/s11060-006-9256-4

    authors: Ryu S,Kolozsvary A,Jenrow KA,Brown SL,Kim JH

    更新日期:2007-04-01 00:00:00